Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 8/20 | 0.54 |
| ▸ | CA2 | P00918 | 8/20 | 0.54 |
| ▸ | CA12 | O43570 | 6/20 | 0.54 |
| ▸ | CA9 | Q16790 | 6/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3871437 | 1.00 | TDP1 (0.67) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL19611966 | 0.98 | TDP1 (0.64) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL7242095 | 0.95 | TDP1 (0.59) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL4648803 | 0.91 | TDP1 (0.53) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL14958603 | 0.90 | TDP1 (0.55) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL22602535 | 0.89 | TDP1 (0.53) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL7148142 | 0.87 | TDP1 (0.51) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL22602576 | 0.87 | TDP1 (0.51) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL137629 | 0.87 | TDP1 (0.85) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL134329 | 0.87 | TDP1 (0.85) | TDP1MAOAMAOBMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070104645-A1 | Chelate based scaffolds in tumor targeting | PARK FUNDING, LLC | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070104645-A1 | Chelate based scaffolds in tumor targeting | ITGB3, ITGB1, ITGA2B | TDP1 4856/4885MAOA 4751/4885MAOB 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.